Guardant Health Inc., a leading precision oncology company, has announced the approval of new compensation terms for 189 newly hired non-executive employees. On July 22, 2025, the company's Compensation Committee approved the granting of restricted stock units (RSUs) representing 239,565 shares of common stock and two non-qualified stock option awards to purchase 23,542 shares. The RSUs and stock options have a grant date of August 1, 2025, with an exercise price set at $41.42 per share. These equity awards are part of the 2023 Employment Inducement Incentive Award Plan, designed to attract new talent. The stock options vest over a three-year period, with one-third of the shares vesting after the first year and continuing monthly thereafter. Similarly, the RSUs vest annually over three years, contingent on ongoing employment.